Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Author: , BarchukWilliam, BoehnckeWolf-Henning, DeodharAtul, DongBin, GottliebAlice B, HsiaElizabeth C, WangYuhua, XuXie L, ZhuangYanli

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the efficacy and safety of guselkumab, a human monoclonal antibody targeting interleukin 23, for treating active psoriatic arthritis, considering its approval for moderate-to-severe psoriasis.
Paper Details　
Original Abstract of the Article :
Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselk...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(18)30952-8

データ提供：米国国立医学図書館（NLM）

Guselkumab: A New Oasis for Psoriatic Arthritis?

Psoriatic arthritis, a condition that affects both the skin and joints, can be a real desert storm for those who suffer from it. This study explores the efficacy and safety of guselkumab, a monoclonal antibody, in treating active psoriatic arthritis. Think of it as a new camel breed, specifically trained to navigate through the turbulent sandstorms of this disease. Researchers conducted a phase 2 study to assess the effects of guselkumab, comparing it to a placebo. This is like dividing a group of travelers into two separate caravans, one receiving a specially crafted camel saddle to improve their journey through the desert while the other continues with their traditional saddle.

Guselkumab: A Potential New Weapon Against Psoriatic Arthritis

The results of this study indicate that guselkumab shows promise in treating active psoriatic arthritis. It’s like finding a hidden oasis that provides respite from the harsh conditions of this disease. Researchers observed positive outcomes in reducing symptoms of psoriatic arthritis, suggesting that guselkumab could offer a new treatment option. It’s like discovering a new route through the desert, leading to a smoother and more comfortable journey for those suffering from this debilitating condition.

Hope on the Horizon: Navigating the Psoriatic Arthritis Desert

This research offers hope for those seeking a new treatment option for active psoriatic arthritis. It’s like finding a new, sturdy camel breed that can withstand the harsh conditions of the desert. Further research is needed to confirm the long-term safety and efficacy of guselkumab, but this study provides a promising starting point. It’s a reminder that even in the most challenging deserts, there is always hope for a better future.

Dr.Camel's Conclusion

Guselkumab holds the potential to be a valuable tool in the fight against psoriatic arthritis. It’s like a new well discovered in a thirsty desert, offering hope for relief and a brighter future. This study encourages further research and exploration to solidify its role in treating this complex and often debilitating disease.

Date :
  1. Date Completed 2018-10-31
  2. Date Revised 2020-09-21
Further Info :

Pubmed ID

29893222

DOI: Digital Object Identifier

10.1016/S0140-6736(18)30952-8

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.